Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OWP-106
- Development stage
- Preclinical
- Lead developer
- OWP Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OWP-106 is an investigational, preclinical-stage oral liquid small molecule formulation under development by OWP Pharmaceuticals for the treatment of psychiatric disorders. OWP Pharmaceuticals focuses on reformulating established central nervous system (CNS) drugs into patient-friendly oral liquid suspensions or solutions via the FDA's 505(b)(2) regulatory pathway. This approach is designed to improve compliance and ease of administration for pediatric, adolescent, and geriatric populations, or other patients who experience dysphagia (difficulty swallowing tablets). While the developer has disclosed a pipeline of reformulated CNS agents—including duloxetine, quetiapine, trazodone, and atomoxetine—the specific active pharmaceutical ingredient for OWP-106 remains undisclosed in public sources.
Beyond the preview
Go deeper on OWP-106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OWP-106.